Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Tandem Diabetes Care Inc (NASDAQ: TNDM) closed the day trading at $31.73 up 4.27% from the previous closing price of $30.43. In other words, the price has increased by $4.27 from its previous closing price. On the day, 1.02 million shares were traded. TNDM stock price reached its highest trading level at $31.92 during the session, while it also had its lowest trading level at $30.12.
Ratios:
For a better understanding of TNDM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.02 and its Current Ratio is at 3.83. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.27.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on March 26, 2024, Upgraded its rating to Buy and sets its target price to $37 from $24 previously.
On August 04, 2023, Citigroup Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $45 to $33.
BofA Securities Downgraded its Neutral to Underperform on May 05, 2023, whereas the target price for the stock was revised from $45 to $33.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 27 ’23 when Allen Dick bought 5,000 shares for $18.96 per share. The transaction valued at 94,778 led to the insider holds 19,962 shares of the business.
Vosseller Leigh bought 6,200 shares of TNDM for $95,395 on Nov 08 ’23. The EVP & CHIEF FINANCIAL OFFICER now owns 11,860 shares after completing the transaction at $15.39 per share. On Nov 08 ’23, another insider, Hansen Shannon Marie, who serves as the Chief Legal Officer of the company, bought 1,935 shares for $15.44 each. As a result, the insider paid 29,884 and bolstered with 1,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 2048599808 and an Enterprise Value of 2034927872. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.74 while its Price-to-Book (P/B) ratio in mrq is 6.63. Its current Enterprise Value per Revenue stands at 2.722 whereas that against EBITDA is -14.666.
Stock Price History:
The Beta on a monthly basis for TNDM is 1.16, which has changed by -0.12661713 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, TNDM has reached a high of $40.92, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 6.93%, while the 200-Day Moving Average is calculated to be 23.97%.
Shares Statistics:
Over the past 3-months, TNDM traded about 1.74M shares per day on average, while over the past 10 days, TNDM traded about 1101340 shares per day. A total of 65.55M shares are outstanding, with a floating share count of 64.13M. Insiders hold about 0.68% of the company’s shares, while institutions hold 110.92% stake in the company. Shares short for TNDM as of 1711584000 were 9312795 with a Short Ratio of 5.36, compared to 1709164800 on 4902804. Therefore, it implies a Short% of Shares Outstanding of 9312795 and a Short% of Float of 15.86.
Earnings Estimates
Investors are keenly observing as 12 analysts analyze and rate the current performance of Tandem Diabetes Care Inc (TNDM) in the stock market.On average, analysts expect EPS of $-0.76 for the current quarter, with a high estimate of $-0.58 and a low estimate of $-0.85, while EPS last year was $-0.63. The consensus estimate for the next quarter is $-0.5, with high estimates of $-0.35 and low estimates of $-0.65.
Analysts are recommending an EPS of between $-1.36 and $-1.96 for the fiscal current year, implying an average EPS of $-1.59. EPS for the following year is $-1.09, with 13 analysts recommending between $-0.7 and $-1.44.
Revenue Estimates
16 analysts predict $174.02M in revenue for the current quarter. It ranges from a high estimate of $179.8M to a low estimate of $166M. As of the current estimate, Tandem Diabetes Care Inc’s year-ago sales were $170.23M, an estimated increase of 2.20% from the year-ago figure. For the next quarter, 15 analysts are estimating revenue of $205.03M, an increase of 3.90% over than the figure of $2.20% in the same quarter last year. There is a high estimate of $220.15M for the next quarter, whereas the lowest estimate is $192M.
A total of 17 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $852.29M, while the lowest revenue estimate was $799M, resulting in an average revenue estimate of $845.31M. In the same quarter a year ago, actual revenue was $747.72M, up 13.10% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $942.58M in the next fiscal year. The high estimate is $1.01B and the low estimate is $903.62M. The average revenue growth estimate for next year is up 11.50% from the average revenue estimate for this year.
